p16INK4a, PTEN, E-cadherin, Bcl-2 and Ki-67 expression in prostate cancer: Its relationship with the metastatic potential and known prognostic factors

Korean Journal of Pathology

Volumn 44, Issue 6, 2010, Pages 597-604

  Park, Seok Ju ^a   Sung, Woo Jung ^a   Kim, Mi Jin ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

bcl 2; Cadherins; Ki 67 antigen; Prostatic neoplasms; PTEN protein, human

Indexed keywords

EID: 79751476787     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2010.44.6.597     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Cancer facts and figures 2009 in Korea [Internet]. Goyang: National Cancer Center; 2009 [cited 2010 Apr 15]. Available from: http://www.ncc.re.kr.
3. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002; 167: 103-11.
4. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 858-87.
5. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
6. Mol AJ, Geldof AA, Meijer GA, van der Poel HG, van Moorselaar RJ. New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration. J Cancer Res Clin Oncol 2007; 133: 687-95.
7. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42.
8. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21: 3573-9.
9. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-88.
10. Merseburger AS, Kuczyk MA, Serth J, et al. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 2003; 10: 223-8.
11. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 2005; 25: 3123-33.
12. Nariculam J, Freeman A, Bott S, et al. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors
13. Bray K, Chen HY, Karp CM, et al. Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res 2009; 7: 1487-96.
14. Smith AJ, Karpova Y, D'Agostino Jr R, Willingham M, Kulik G. Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One 2009; 4: e6224.
15. Royuela M, Arenas MI, Bethencourt FR, Sánchez-Chapado M, Fraile B, Paniagua R. Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur Cytokine Netw 2001; 12: 654-63.
16. McDonnell TJ, Chari NS, Cho-Vega JH, et al. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics 2008; 1: 1.
17. Iemelynova AA, Grygorenko VM, Cheremuha SV, Romanenko AM. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation. Exp Oncol 2009; 31: 246-9.
18. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 2001; 32: 690-7.
19. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 661-8.
20. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol 2005; 23: 402-6.
21. Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in beta-catenin expression and localization in prostate cancer. Prostate 2008; 68: 1196-205.
22. Shah GV, Muralidharan A, Gokulgandhi M, Soan K, Thomas S. Cad-herin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer. J Biol Chem 2009; 284: 1018-30.
23. Chakravarti A, Heydon K, Wu CL, et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol 2003; 21: 3328-34.
24. Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 2007; 25: 3082-9.
25. Zhang Z, Rosen DG, Yao JL, Huang J, Liu J. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol 2006; 19: 1339-43.
26. Jarrard DF, Modder J, Fadden P, et al. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 2002; 185: 191-9.
27. Schmitz M, Grignard G, Margue C, et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120: 1284-92.
28. Wu Z, McRoberts KS, Theodorescu D. The role of PTEN in prostate cancer cell tropism to the bone micro-environment. Carcinogenesis 2007; 28: 1393-400.
29. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860-7.
30. Bubendorf L, Sauter G, Moch H, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437-41.